Strs Ohio Sells 15,000 Shares of Biohaven Ltd. (NYSE:BHVN)

Strs Ohio decreased its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 62.2% during the 4th quarter, Holdings Channel reports. The firm owned 9,100 shares of the company’s stock after selling 15,000 shares during the quarter. Strs Ohio’s holdings in Biohaven were worth $389,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Simon Quick Advisors LLC boosted its holdings in Biohaven by 36.3% in the fourth quarter. Simon Quick Advisors LLC now owns 74,968 shares of the company’s stock worth $3,209,000 after acquiring an additional 19,968 shares in the last quarter. Citigroup Inc. boosted its holdings in Biohaven by 97.9% in the third quarter. Citigroup Inc. now owns 146,907 shares of the company’s stock worth $3,821,000 after acquiring an additional 72,673 shares in the last quarter. Legato Capital Management LLC bought a new position in Biohaven in the fourth quarter worth approximately $469,000. Monashee Investment Management LLC boosted its holdings in Biohaven by 80.0% in the third quarter. Monashee Investment Management LLC now owns 90,000 shares of the company’s stock worth $2,341,000 after acquiring an additional 40,000 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Biohaven in the third quarter worth approximately $923,000. Institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the topic of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, April 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a report on Thursday, April 18th. UBS Group raised their target price on Biohaven from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, April 23rd. TD Cowen raised their target price on Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a report on Friday, March 1st. Finally, HC Wainwright raised their target price on Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a report on Monday, March 4th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Biohaven has a consensus rating of “Buy” and an average price target of $52.13.

Insiders Place Their Bets

In other news, Director Gregory Bailey bought 25,503 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was acquired at an average cost of $39.18 per share, with a total value of $999,207.54. Following the completion of the transaction, the director now directly owns 1,600,071 shares of the company’s stock, valued at approximately $62,690,781.78. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Gregory Bailey bought 25,503 shares of the firm’s stock in a transaction on Wednesday, April 24th. The stock was acquired at an average cost of $39.18 per share, with a total value of $999,207.54. Following the completion of the transaction, the director now directly owns 1,600,071 shares of the company’s stock, valued at approximately $62,690,781.78. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Vlad Coric bought 121,951 shares of the firm’s stock in a transaction on Monday, April 22nd. The stock was purchased at an average cost of $41.00 per share, with a total value of $4,999,991.00. Following the completion of the transaction, the chief executive officer now directly owns 1,788,417 shares of the company’s stock, valued at $73,325,097. The disclosure for this purchase can be found here. Insiders bought 196,234 shares of company stock valued at $7,999,179 over the last ninety days. 16.00% of the stock is currently owned by insiders.

Biohaven Trading Up 1.1 %

Shares of BHVN opened at $38.97 on Monday. The company has a market capitalization of $3.44 billion, a price-to-earnings ratio of -6.89 and a beta of 1.18. The stock has a 50 day moving average of $50.90 and a 200 day moving average of $42.07. Biohaven Ltd. has a 12 month low of $12.35 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN) last released its earnings results on Thursday, February 29th. The company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, equities research analysts predict that Biohaven Ltd. will post -5.81 earnings per share for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.